In this webinar, Dr. Jason Sager discusses standard treatments and innovative treatments available to patient in clinical trials. He reviews recent data and paper published that is advancing what we know about how to treat TNBC.
Get Your Own Cancer Questions Answered
TOPICS COVERED:
0:00 - Introductions
1:03 - What is Triple Negative Breast Cancer?
5:05 - Defining Metastatic in Breast Cancer
6:51 - Standard Treatments for Metastatic Triple Negative Breast Cancer
8:50 - Why is my doctors recommending 24 weeks of chemotherapy and radiation prior to surgery?
16:33 - Involving a Radiation Oncologist and Medical Oncologist to your surgical team
18:53 - Reviewing a Treatment Recommendation
23:58 - NextGen Tumor Sequencing for TNBC and Matching to Clinical Trials
29:50 - Immunotherapy Trials in New England for TNBC
32:05 - Do you need to redo scans, biopsy, and tests if you get a second opinion at another cancer center?
34:15 - Using Existing Biopsy to get NextGen Sequencing performed
34:55 - Monitoring Triple Negative Breast Cancer for Recurrence. What does the latest data say?
41:39 - Testing strategies for proactive patients
References mentioned by Dr. Sager
FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer
FDG PET, PET/CT, and breast cancer imaging
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Jason Sager, MD is an oncologist and drug developer that helps patients understand their options and reach their best possible outcome.
Most patients are handed a treatment plan and told to begin. But what if there are better options—or steps being missed?
This free 5-day email series helps you understand the hidden opportunities that could shape your care. It covers what many patients wish they had known sooner—before key decisions were made.
You’ll get insights on:
Each short email builds on the last, helping you feel more informed and in control—right when decisions matter most.
Join hundreds of patients gaining clarity and confidence—in just 5 short emails.
